In March 2025, the company introduced new designs to get a direct-to-consumer offering of its Wegovy weight loss drug. The company set up a completely new pharmacy, known as NovoCare, which would demand consumers $499 each month for entry to the drug, fewer than 50 % the price of the drug by means of other pharmaceutical distribution networks.[53]i